Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC

Inclusion Criteria: * Patients with newly histologically confirmed non-keratinizing (according to World Health Organization (WHO 2005) histologically type). * A Karnofsky performance status of at least 80; * Tumor staged is according to the 7th American Joint Commission on Cancer edition as Stage III：T1-2N2M0, T3N0-2M0 Stage IVa：T4N0-2M0 Stage IVb：Any T、N3. * Adequate marrow: a WBC ≥3.5×109 l-1; a platelet count ≥100×109 l-1; and hemoglobin levels ≥100 g/l. * Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) \<1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤2.5×ULN, and bilirubin ≤ULN. * Adequate renal function: a creatinine clearance rate of at least 60 mL/min. * Patients must be informed of the investigational nature of this study and give written informed consent. Exclusion Criteria: * WHO Type keratinizing squamous cell carcinoma. * Age \>65 years or \<18 years. * Distant metastasis, * Treatment with palliative intent. * Pregnancy or lactation. * a history of previous radiotherapy in the nasopharyngeal region or previous chemotherapy. * history of renal disease, unstable cardiac disease requiring treatment.